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Acute promyelocytic leukemia has good prognosis in view of the high complete remission
and survival rates achieved with therapies containing all-trans retinoic acid or arsenic tri-
oxide. However, there is a signiﬁcant risk of death during induction due to hemorrhage
secondary to disseminated intravascular coagulation. This has contributed to a gap in the
prognosis of patients between developed and developing countries. The International Con-
sortium on Acute Promyelocytic Leukemia was created in 2005 and proposed a treatment
protocol based on daunorubicin and all-trans retinoic acid stratiﬁed by risk geared toward
developing countries. Herein are presented the results from the ﬁrst patient cohort treated
in  a single developing country hospital employing a slightly modiﬁed version of the Interna-
tional Consortium protocol in a real life setting. Twenty patients with acute promyelocytic
leukemia were enrolled: 27.8% had low-risk, 55.6% intermediate risk and 16.7% high-risk.
The complete remission rate was 94.4% after a median of 42 days. Both relapse rates and
death rates were one patient (5.5%) each. No deaths were observed during consolidation.
After a median follow-up of 29 months, the overall survival rate was 89.1%. Efﬁcacy and
safety  of the International Consortium on Acute Promyelocytic Leukemia protocol has been
reproduced in acute promyelocytic leukemia patients from a developing country.©  2016 Associac¸a˜o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by  Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license∗ Corresponding author at: Instituto Nacional de Ciencias Médicas y N
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did not fulﬁll DIC criteria (Table 1).
The induction, consolidation and maintenance regimens
were the same as those used by the IC-APL 200613; they were
applied without any modiﬁcation (Figure 1).
Table 1 – Baseline characteristics of the patients.
Median (range)
Age (years) 40 (21–74)
Hemoglobin (g/dL) 8.2 (3.2–13.1)
White blood cells (×109/L) 1.75 (0.2–15.90)
Absolute neutrophil count (×109/L) 0.079 (0–13,880)
Promyelocytes (%) 17.5 (0–96)
Platelets (×109/L) 43.5 (9–108)
PT (s) 11.9 (9.2–14.7)
aPTT (s) 27.1 (22–38.4)
TT (s) 16.9 (13.8–23.1)
Fibrinogen (mg/dL) 263 (88–901)
D-dimer (g/L) 3467 (682–6570)
Promyelocytes in bone marrow (%) 81.5 (3–96)
Blasts in bone marrow (%) (0–80)a
PT: prothrombin time; aPTT: activated partial thromboplastin time;286  rev bras hematol hem
Introduction
Acute promyelocytic leukemia (APL) is a clinical and biolog-
ical variant of acute myeloid leukemia (AML) characterized
by a predominance of abnormal promyelocytes. According to
the World Health Organization (WHO), it is currently classiﬁed
among the AML  with recurrent cytogenetic abnormalities [APL
and t(15;17)(q22;q12);PML-RARA].1 Untreated, APL is the most
aggressive form of AML, with a median survival of under one
month.2 It is mainly diagnosed in young adults aged between
20 and 59. Some studies have suggested an increased inci-
dence in Latinos (24.3% vs. 8.3% in non-Latino populations)
but this appears to reﬂect a selection and referral bias.3,4
We  recently reported that this type of leukemia accounts for
10.5% of all acute leukemias and 21% of AML at the Instituto
Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
(INCMNSZ).5
Since the introduction of all-trans retinoic acid (ATRA) in
1988 by Huang in Shangai, complete remission (CR) rates of
85% changed the natural history of this disease.6 The Ital-
ian Group for Adult Hematologic Diseases (GIMEMA) reported
their experience with regimens including ATRA in combi-
nation with anthracyclines, obtaining high CR rates and
encouraging disease-free survival (DFS) and overall survival
rates (OS).7,8
In 1999, Sanz et al. designed a risk-adapted strategy
after observing that patients with high white blood counts
(>10 × 109/L) and low platelet counts (<40 × 109/L) were at high
risk of death during induction and relapse.9 Their study added
ATRA to the consolidation regimens in intermediate and high-
risk patients. Improvements in treatment have transformed
this leukemia into the one with the best survival rates in adults
today.
In developed countries, CR rates in APL patients are close
to 95% with DFS curves at two years between 87% and 97%.9,10
However, some studies in developing countries reported CR
rates of 67.9%, death during induction in 32% of cases and an
OS below 60% in 2005.11 The main cause of death during induc-
tion was hemorrhage followed by differentiation syndrome.
The current basis of therapy of APL patients hinges on the
use of speciﬁc agents that induce differentiation, such as ATRA
and arsenic trioxide (ATO) in conjunction with chemother-
apeutic agents such as anthracyclines.12 ATRA and arsenic
trioxide are drugs whose costs are prohibitive to a large group
of patients in developing countries.
The International Consortium on Acute Promyelocytic
Leukemia (IC-APL) was created in 2005 in order to narrow
the gap between the response rates reported in developed
countries and those in some developing countries. Its pur-
pose was to integrate an inter-institutional web designed
program to generate and implement diagnostic and thera-
peutic strategies for APL patients in developing countries.
This endeavor was supported by expert North American
and European work groups. The targeted countries included
Brazil, Mexico, Chile and Uruguay. The IC-APL implemented
the regimen designed by the Programa para el Estudio de
la Terapéutica en Hemopatía Maligna (PETHEMA)/Dutch-
Belgian Hemato-Oncology Cooperative Group (HOVON) LPA
2005, in which idarubicin was replaced by daunorubicin 2 0 1 6;3  8(4):285–290
(equivalence: daunorubicin 5 mg  = idarubicin 1 mg)  in induc-
tion and consolidation therapy. This substitution was mainly
due to economic limitations. The regimen and its results were
recently published.13 CR rates were 85% with a 15% mortality
during induction and 5% during consolidation. Median follow-
up was 28 months with a relapse rate of 4.5%, OS 80% and DFS
91%.13
The Department of Hematology and Oncology of the
INCMNSZ participated in the Consortium’s original series with
the inclusion of two patients. Because of logistic aspects, we
could not include more  patients. Due to the encouraging pre-
liminary data at the time, this regimen was later adopted as
ﬁrst-line therapy in APL patients treated at the INCMNSZ as of
January 2007. By June 2013, 18 more  patients had been treated
with this regimen, but not included into the original Consor-
tium study. Patient characteristics, response to treatment and
survival are described in this retrospective study of a real-life
scenario.
Methods
A retrospective cohort study was carried out of adult patients
with APL t(15;17)(q22;q12);PML-RARA, treated in the Acute
Leukemia Clinic, Department of Hematology and Oncology of
the INCMNSZ, between January 2007 and June 1, 2013. The
diagnosis of APL t(15;17) was established according to the
WHO  criteria.1 Morphological and cytogenetic studies were
conducted in all patients (conventional karyotype and FISH
with a probe for PML/RARA) in a bone marrow sample obtained
at diagnosis. Disseminated intravascular coagulation (DIC)
was deﬁned in accordance with the International Society for
Thrombosis and Hemostasis criteria (ISTH) if scores were 5
or above.14 Coagulopathy was deﬁned as the prolongation of
coagulation times (PT or PTT) or a decrease in ﬁbrinogen thatTT: thrombin time.
a 80% myeloid blast count was reported in the initial bone marrow
aspirate in a patient with the micro-granular variant of APL.
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Induction
DNR 60mg/m2/d
(days 2,4,6,8) ∗
ATRA 45mg/m2/d
(from day 1 to CR)
Low risk
DNR: 25mg/m2/d (1-4)
ATRA 45mg/m2/d (1-15)
DNR: 35mg/m2/d (1-4)
ATRA 45mg/m2/d (1-15)
DNR: 25mg/m2/d (1-4)
Ara-C 1000mg/m2/d (1-4)
ATRA 45mg/m2/d (1-15)
DNR: 60mg/m2/d (1)
Ara-C 150mg/m2/8hrs (1-5)
ATRA 45mg/m2/d (days 1-15)
ATRA: 45mg/m2/d (days 1 to 15) every 3 months +
methotrexate: 15mg/m2/d, weekly + 6-mercaptopurine: 50mg/m 2/d
DNR: 25mg/m2/d (1,2)
ATRA 45mg/m2/d (1-15)
DNR: 25mg/m2/d (1)
ATRA 45mg/m2/d (1-15)
MTZ 10mg/m/d (1-5)
ATRA 45mg/m2/d (1-15)
MTZ 10mg/m/d (1-3)
ATRA 45mg/m2/d (1-15)
MTZ 10mg/m/d (1-3)
ATRA 45mg/m2/d (1-15)
Intermediate risk High risk ±
Consolidation
Maintenance (2 years)
Figure 1 – Induction, consolidation and maintenance regimens.
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as administered with dexamethasone 2.5 mg/m2 q 12 h
or two weeks, in patients with a white blood cell count
5 × 109/L. Patients at high-risk and over age 60 were treated as
ntermediate-risk patients. Maintenance was initiated when
ematological recovery was achieved, usually one month after
he last consolidation. Support measures during induction
nd consolidation strictly adhered to the recommendations
f the European LeukemiaNet.15
Toxicity was evaluated according to the National Cancer
nstitute common toxicity criteria scale (version 4.03).16 The
nly modiﬁcation to the original protocol was the adminis-
ration of prophylactic intrathecal chemotherapy to patients
onsidered to be at high-risk; it consisted of methotrexate
12.5 mg)  and cytarabine (60 mg), every month, six dosages,
nce all three systemic consolidations had been concluded.
odiﬁcations were made in monitoring during follow-up –
valuation of minimal residual disease was not performed. At
hat time, PML/RARA breakpoints were not identiﬁed in our
enter.Statistics  and  ethics
This study was approved by our local Ethics Committee,
governed by the principles established in the Declaration
of Helsinki for research in humans. Due to the retrospec-
tive nature of this report, a consent form was not required;
however at our center, we  routinely request written autho-
rization for chemotherapy administration and the patient is
informed on the risks and beneﬁts. Continuous variables are
described as medians and intervals while categorical variables
are presented as frequencies and proportions. Between-group
differences were established with Mann–Whitney U or Chi
square tests for numerical and categorical variables, respec-
tively. Survival curves were created using the Kaplan–Meier
method. The SPSS v 15.0 statistical package was used.Results
Twenty patients were included but two requested transfers
to other hospitals during the diagnostic stage, so 18 patients
288  rev bras hematol hemoter.
APL:
n=20
Transfered to other institutions:
n=2
Induction with modified IC-APL:
n=18
Induction mortality:
n=1
Consolidations (3):
n=17
Maintenance:
n=17
Relapse and death
in progresion:
n=1
Lost to follow-up:
n=1
Alive in CR:
n=15
response rates and survival.Figure 2 – Study design.
underwent induction therapy with the modiﬁed IC-APL proto-
col (Figure 2).
Eleven of the 18 evaluated patients (61.1%) were female and
seven (38.9%) were male, a ratio of 1.6:1. Median age at diagno-
sis was 40 with a range of 21–74 years; note that three patients
(16.6%) were over 65 years of age at diagnosis. Of the total
number of patients, ﬁve (27.8%) were classiﬁed as low-risk, 10
(55.6%) were intermediate and three (16.6%) were high-risk.
At diagnosis, ﬁve patients (27.8%) fulﬁlled DIC criteria and
38.9% fulﬁlled those for coagulopathy. None of the patients
had abnormal liver or kidney function test results. Of the 18
analyzed patients, nine (50%) had one or more  comorbidities:
four (22%) had hypothyroidism, two (11%) had type 2 diabetes
mellitus, two (11%) were obese, two (11%) had a history of can-
cer (one patient had had breast and basal cell carcinoma and
the other breast cancer), two (11%) had cardiovascular disease
(one had systemic hypertension and the other had atrial ﬁbril-
lation), one (5.5%) had rheumatoid arthritis, one (5.5%) had
chronic obstructive pulmonary disease (COPD) and one (5.5%)
had relapsing APL and was admitted to the protocol. One of
the patients had multiple comorbidities at the time of diag-
nosis: COPD, obesity, pulmonary tuberculosis, past breast and
basal cell carcinoma, post-radiation pulmonary ﬁbrosis, type
2 diabetes mellitus and hypothyroidism; this was the patient
that died during induction.The morphologic characteristics of the bone marrow
aspirate were analyzed in 17 cases: 16 (94.1%) had a clas-
sic morphology and one case (5.9%) was considered a 2 0 1 6;3  8(4):285–290
variant. The diagnosis of AML  was initially established
in this patient because the variant promyelocytes were
counted as blasts. Immunophenotypes were obtained in 16
patients: 100% had a classic immunophenotype: CD34(−),
HLA-DR(−), CD13(+), CD33(+), and myeloperoxidase(+). The
t(15;17)(q22;q21) translocation was found by karyotype or
FISH in 17 patients (94.4%) and only in one case (5.5%) was
the demonstration of the PML/RARA rearrangement by poly-
merase chain reaction necessary.
Of the 18 patients treated with the modiﬁed IC-APL 2006
regimen, 17 (94.4%) achieved CR in a median of 42 days (range:
34–158 days). One patient died (5.5%) during induction, the
aforementioned patient with multiple comorbidities. Twelve
patients (66.7%) developed grade 3–4 infectious complica-
tions and two (11.1%) developed grade 3–4 non-hematological
complications (subarachnoid hemorrhage and leukocytoclas-
tic vasculitis). The rate of severe febrile neutropenia during
induction was 61.1% (11/18) and was more  frequent in patients
over the age of 65: 100% vs. 53.3%, although this difference was
not statistically signiﬁcant (p-value = 0.2). Differentiation syn-
drome was identiﬁed in four patients (22.2%). Interestingly, a
group of four patients (22%) did not develop severe complica-
tions during induction.
Among the 17 patients in hematologic CR, cytogenetic
remission was corroborated by ﬂuorescence in situ hybridiza-
tion (FISH) in 15; of these, 100% were in complete cytogenetic
remission. Molecular remissions were not analyzed.
Of the 17 patients that achieved CR, 14 (82.3%) received
three programmed consolidations and three patients (17.6%)
received one consolidation one month late; in one case it was
due to economic hardship and in two cases, as a result of
severe treatment-related complications (severe febrile neu-
tropenia and liver toxicity during the second consolidation).
The rate of severe febrile neutropenia during consolidation
was 29.4% (5/17). One patient was lost to follow-up after the
third consolidation but we corroborated that he was alive and
in remission after which we were unable to contact him.
During follow-up, one bone marrow relapse was doc-
umented (5.9%). The patient was administered rescue
chemotherapy and underwent autologous hematopoietic
stem cell transplantation; however, the disease progressed
and led to her death. Of all the studied patients, two died
(11.1%): one, due to post-chemotherapy aplasia during induc-
tion (5.5%) and the other as a result of graft versus host disease
(5.5%). At the time of analysis, the treatment protocol had been
completed by 10 of the 16 patients in remission (62.5%) and the
median overall survival had yet to be reached (Figure 3). After
a follow-up of 29 months, OS was 89.1% and only one patient
had relapsed (5.8%).
Discussion
To date, this is the ﬁrst series of APL patients treated with
the IC-APL protocol after its publication in 2013. Although
the cohort is small, we conﬁrmed the previously publishedAs in the IC-APL and European reports, patients at an
intermediate-risk prevail (55.5% in the current cohort vs.
52–52.9%) but there was a lower incidence of high-risk patients
rev bras hematol hemoter. 2 0
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Figure 3 – Overall survival.
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Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J,16.7% in this cohort vs. 28.17–32%) and a greater incidence of
ow-risk patients (37.8% in this cohort vs. 16–19.1%).13,17
Our data cannot formally be compared with the previous
eport of the IC-APL in terms of superiority or inferiority of
esults because this study was not designed with that goal.
oreover, this study had some limitations such as the small
ample size and short follow-up. However, we think that safety
spects and response to treatment were reproduced. Thus,
ome interesting numbers are worth noting: the CR rate was
4.5% and those described by the original Consortium were
5% and European centers 91–94.3%. In terms of overall sur-
ival, it is slightly above that reported by the consortium (89.1%
s. 80% at two years); both were determined after a short
ollow-up when compared with other reports.13,18,19 Death
ates during induction and consolidation were 5.5% and 0%,
espectively compared to rates of 15% and 5% reported by the
riginal Consortium.13 These rates are superior to those pre-
ented by a Brazilian report before the IC-APL initiative, in
hich death rates during induction and consolidation were
2% and 10%, respectively.11 Also, in comparison with devel-
ped countries, the mortality in the current study is within the
reviously described range: mortality during induction 5–10%
nd <5% during consolidation.9,10,17–19
Hemorrhage is the main cause of death described in the
iterature followed by death due to coagulopathy.13,19 In this
tudy, the rates for both DIC (27.8%) and coagulopathy (38.9%)
ere low;  there were no deaths directly related to hemor-
hages.
There are peculiarities to clotting abnormalities and DIC in
atients with APL. The incidence of DIC may be possibly over-
stimated if the diagnosis is established according to the ISTH
riteria, since thrombocytopenia and increases in D-dimers
core many  points in this classiﬁcation system and they are
lso common ﬁndings in leukemia patients with no other clot-
ing abnormalities.5,14,20 The pathophysiology of ﬁbrinolysis in
atients with APL is also different to that of other DIC causes,
o these criteria should not necessarily be applied to patients
ith APL.20 We  believe that the value of serum ﬁbrinogen is
erhaps the most relevant parameter when deﬁning DIC and 1 6;3  8(4):285–290 289
for therapeutic decision-making in APL patients; in any case,
close dynamic monitoring of these patients is very important
during induction.
To date, no central nervous system (CNS) relapses have
been observed; however, we cannot reach any solid conclu-
sions on prophylactic treatment of these patients since the
sample size was small. CNS prophylaxis with chemotherapy
is currently recommended in patients at high-risk of relapse.21
There are many  reports on the presence of the FLT3-ITD
mutation in APL patients. The frequency of the mutation
is variable (12–38%) and its prognostic value is questionable
since it has not affected survival curves in all reports.22–25
A recent meta-analysis corroborated that APL patients with
the FLT3-ITD mutation have similar CR rates; however, this
mutation does lead to shortened OS and DFS due to a greater
incidence of relapse.25 The FLT3-ITD mutation has also been
correlated to CNS relapse.26 However, to date the presence of
the FLT3-ITD mutation has not been incorporated into thera-
peutic algorithms nor should it be considered in therapeutic
decision-making unless it is in the context of a clinical trial.
Although the number of over 65-year-old patients in this
cohort is small, they all are nevertheless alive and in CR which
coincides with the data reported by other groups that have
described long OS in the elderly.27 It is important to mention
that the over 65-year olds in this study had severe neutropenia
and infectious complications during induction. This under-
scores the importance of supportive care in this group of
patients with APL and in whom curative treatment should
always be the goal.
Patients with APL must be treated in specialized centers.
Mortality risks, particularly during induction, make them very
vulnerable. Although no deaths occurred during consolida-
tion, strict surveillance is also mandatory during this phase.
Efforts should focus on the timely prevention and treatment
of complications during chemotherapy following the recom-
mendations of expert groups.15
Conclusions
This is the ﬁrst cohort of adult patients with APL treated in
one center that reproduces the results of the original IC-APL
protocol. The CR rates and survival curves observed in this
report conﬁrm the effectiveness and safety of this treatment
protocol in a real-life scenario.
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